213 related articles for article (PubMed ID: 8215640)
81. Short-term T cell receptor directed immunotherapy induces organ specific peripheral tolerance in a strongly incompatible rat model.
Dufter C; Post S; Thies J; Otto G; Gaweco A; Meuer S; Terness P
Transpl Immunol; 1994 Dec; 2(4):278-84. PubMed ID: 7704537
[TBL] [Abstract][Full Text] [Related]
82. Donor-specific stimulation of peripheral blood mononuclear cells from recipients of orthotopic liver transplants is associated, in the absence of rejection, with type-2 cytokine production.
Chung SW; Yoshida EM; Cattral MS; Hu Y; Gorczynski RM
Immunol Lett; 1998 Sep; 63(2):91-6. PubMed ID: 9761370
[TBL] [Abstract][Full Text] [Related]
83. CD2 antigen targeting reduces intragraft expression of mRNA-encoding granzyme B and IL-10 and induces tolerance.
Kapur S; Khanna A; Sharma VK; Li B; Suthanthiran M
Transplantation; 1996 Jul; 62(2):249-55. PubMed ID: 8755824
[TBL] [Abstract][Full Text] [Related]
84. Anti-CD3-enhanced interleukin-2 immunotherapy of pulmonary metastases.
Kim B; Warnaka P; Konrad C
J Surg Res; 1991 May; 50(5):480-4. PubMed ID: 1828097
[TBL] [Abstract][Full Text] [Related]
85. T10B9 action: the effect of anti-T-cell antibody mitogenicity and graft rejection on the first dose cytokine response.
Brown S; Lucas B; Waid T; McKeown W; Tsuchida M; Thompson J
Transplant Proc; 1997; 29(1-2):315-6. PubMed ID: 9123017
[No Abstract] [Full Text] [Related]
86. Interleukin (IL) 4, the cytokine that isn't there: reactivity of IL-4 antibodies with cells in IL-4 -/- mice.
Mottram PL; Purcell LJ; Han WR; Maguire J; Stein-Oakley AN
Transplantation; 1997 Mar; 63(6):911-4. PubMed ID: 9089237
[TBL] [Abstract][Full Text] [Related]
87. Activation of T lymphocytes for adhesion and cytokine expression by toxin-conjugated anti-CD3 monoclonal antibodies.
Hamawy MM; Tsuchida M; Manthei ER; Dong Y; Fechner JE; Knechtle JS
Transplantation; 1999 Sep; 68(5):693-8. PubMed ID: 10507490
[TBL] [Abstract][Full Text] [Related]
88. Intragraft overexpression of interleukin-4 is neither sufficient nor essential for tolerance induction to cardiac allografts in a high-responder strain combination.
Ritter T; Risch K; Schroder G; Kolls J; Siegling A; Graser E; Reinke P; Brock J; Lehmann M; Volk HD
Transplantation; 1999 Nov; 68(9):1427-31. PubMed ID: 10573088
[TBL] [Abstract][Full Text] [Related]
89. Inhibition of DNA synthesis and IL-2 bioactivity in MLR by splenic pregnancy-associated natural suppressor cells involves the production of a TGF-beta 1-like molecule and a second distinct inhibitory factor.
Brooks-Kaiser JC; Hoskin DW
J Reprod Immunol; 1993 Sep; 25(1):31-49. PubMed ID: 8271238
[TBL] [Abstract][Full Text] [Related]
90. Transplant tolerance modifying antibody to CD200 receptor, but not CD200, alters cytokine production profile from stimulated macrophages.
Gorczynski RM
Eur J Immunol; 2001 Aug; 31(8):2331-7. PubMed ID: 11477545
[TBL] [Abstract][Full Text] [Related]
91. Anti-transferrin receptor monoclonal antibody: a novel immunosuppressant.
Woodward JE; Bayer AL; Chavin KD; Boleza KA; Baliga P
Transplantation; 1998 Jan; 65(1):6-9. PubMed ID: 9448136
[TBL] [Abstract][Full Text] [Related]
92. Monoclonal antibody treatment (anti-CD4 and anti-interleukin-2 receptor) combined with cyclosporin A has a positive but not simple dose-dependent effect on rat renal allograft survival.
Steinbrüchel DA; Koch C; Kristensen T; Kemp E
Scand J Immunol; 1991 Nov; 34(5):627-33. PubMed ID: 1947798
[TBL] [Abstract][Full Text] [Related]
93. Activation of beta(1) integrins mediates proliferation and inhibits apoptosis of intestinal CD4-positive lymphocytes.
Stallmach A; Giese T; Pfister K; Wittig BM; Künne S; Humphries M; Zeitz M; Meuer SC
Eur J Immunol; 2001 Apr; 31(4):1228-38. PubMed ID: 11298349
[TBL] [Abstract][Full Text] [Related]
94. Effects of anti-transforming growth factor-beta antibody and interleukin-2 in tumor-bearing mice.
Gridley DS; Sura SS; Uhm JR; Lin CH; Kettering JD
Cancer Biother; 1993; 8(2):159-70. PubMed ID: 7804355
[TBL] [Abstract][Full Text] [Related]
95. Prolongation of skin allografts by recombinant tumor necrosis factor and interleukin-1.
Parenteau GL; Doherty GM; Peplinski GR; Tsung K; Norton JA
Ann Surg; 1995 May; 221(5):572-7; discussion 577-8. PubMed ID: 7748039
[TBL] [Abstract][Full Text] [Related]
96. Tumor necrosis factor-alpha mediates the release of bioactive transforming growth factor-beta in murine microglial cell cultures.
Chao CC; Hu S; Sheng WS; Tsang M; Peterson PK
Clin Immunol Immunopathol; 1995 Dec; 77(3):358-65. PubMed ID: 7586747
[TBL] [Abstract][Full Text] [Related]
97. The effect of anti-interleukin 2 monoclonal antibody treatment on the survival of rat cardiac allograft.
Sakagami K; Ohsaki T; Ohnishi T; Saito S; Matsuoka J; Orita K
J Surg Res; 1989 Mar; 46(3):262-6. PubMed ID: 2646474
[TBL] [Abstract][Full Text] [Related]
98. Prolonged allograft survival by the inhibition of costimulatory CD2 signals but not by modulation of CD48 (CD2 ligand) in the rat.
Sido B; Otto G; Zimmermann R; Müller P; Meuer S; Dengler TJ
Transpl Int; 1996; 9 Suppl 1():S323-7. PubMed ID: 8959856
[TBL] [Abstract][Full Text] [Related]
99. A highly selective inhibitor of IkappaB kinase, BMS-345541, augments graft survival mediated by suboptimal immunosuppression in a murine model of cardiac graft rejection.
Townsend RM; Postelnek J; Susulic V; McIntyre KW; Shuster DJ; Qiu Y; Zusi FC; Burke JR
Transplantation; 2004 Apr; 77(7):1090-4. PubMed ID: 15087776
[TBL] [Abstract][Full Text] [Related]
100. Monoclonal anti-tumor necrosis factor-alpha antibody treatment of rat cardiac allografts: synergism with low-dose cyclosporine and immunohistological studies.
Seu P; Imagawa DK; Wasef E; Olthoff KM; Hart J; Stephens S; Dempsey RA; Busuttil RW
J Surg Res; 1991 May; 50(5):520-8. PubMed ID: 2038191
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
